Skip to main content

Table 3 Hazard ratios of breast cancer across tertiles of BMI by clusters of breast tumors from hierarchical clustering (see Fig. 1)a

From: Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study

  Postmenopausal non-users of HTb Postmenopausal users of HTb Pre- and perimenopausal womenb
  Cases (n) HR CI (95%)   Cases (n) HR CI (95%)   Cases (n) HR CI (95%)
Cluster 1 Tertile 1 4 1   Tertile 1 30 1   Tertile 1 59 1  
(ER+, PR+, HER2-, Ki67 low , bcl-2+, and p53-) Tertile 2 8 1.02 (0.31,3.40) Tertile 2 32 0.74 (0.44,1.22) Tertile 2 31 0.64 (0.41,1.00)
Tertile 3 33 2.50 (0.86,7.23) Tertile 3 24 0.61 (0.35,1.06) Tertile 3 21 0.55 (0.33,0.93)
Per 5 kg/m 2   1.44 (1.10,1.90) Per 5 kg/m 2   0.68 (0.50,0.94) Per 5 kg/m 2   0.85 (0.67,1.08)
p trend   0.009   p trend   0.018   p trend   0.19  
Cluster 2 Tertile 1 5 1   Tertile 1 10 1   Tertile 1 18 1  
(ER- or ER+ that are Bcl-2-) Tertile 2 6 0.77 (0.23,2.56) Tertile 2 18 1.14 (0.52,2.53) Tertile 2 9 0.59 (0.26,1.32)
Tertile 3 16 1.40 (0.49,4.04) Tertile 3 6 0.43 (0.15,1.21) Tertile 3 20 1.52 (0.77,3.00)
Per 5 kg/m 2   1.15 (0.78,1.70) Per 5 kg/m 2   0.83 (0.52,1.32) Per 5 kg/m 2   1.22 (0.91,1.62)
p trend   0.47   p trend   0.42   p trend   0.18  
Cluster 3 Tertile 1 5 1   Tertile 1 20 1   Tertile 1 48 1  
(ER+ with at least one other marker indicative of higher aggressiveness) Tertile 2 21 2.98 (1.01,8.75) Tertile 2 33 1.20 (0.68,2.12) Tertile 2 26 0.72 (0.44,1.18)
Tertile 3 16 1.57 (0.51,4.83) Tertile 3 17 0.77 (0.39,1.51) Tertile 3 31 1.13 (0.70,1.82)
Per 5 kg/m 2   1.00 (0.71,1.42) Per 5 kg/m 2   0.82 (0.58,1.15) Per 5 kg/m 2   0.94 (0.74,1.19)
p trend   0.99   p trend   0.24   p trend   0.60  
  1. Median (p25, p75) values of BMI: Tertile 1: 21.4 (20.4, 22.3), Tertile 2: 24.8 (23.9, 25.7); Tertile 3: 29.9 (28.1, 32.7)
  2. No statistical heterogeneity of HRs across subtypes was observed
  3. aFrom Cox regression models adjusted for height, number of full-term pregnancies, pill use, education level, smoking status, and study center bAt baseline (HT hormone therapy)